Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate Therapy
New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for ro...
Saved in:
Published in | American journal of clinical pathology Vol. 137; no. 4; pp. 572 - 574 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Chicago, IL
American Society of Clinical Pathologists
01.04.2012
Oxford University Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide clinical management. We report herein the application of a recently described plasma-diluted thrombin time (DTI assay) used to monitor intravenous DTI as a useful and easily implemented method to monitor oral DTIs. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0002-9173 1943-7722 |
DOI: | 10.1309/AJCPAU7OQM0SRPZQ |